

Comments in Response to the 60 Day Federal Register Notice

A 60-day notice was published in the **Federal Register** in Vol. 82, No. 117, pg. 28068 on June 20, 2017. No comments were received.

Annual Burden Estimates

ACL estimates the burden of this collection of information as follows: 56 State Units on Aging (SUA) respond semi-annually which have an average

estimated burden of 2 hours per grantee for a total of 112 hours per submission.

The proposed data collection tool may be found on the ACL Web site for review at: <https://www.acl.gov/about-acl/public-input>.

Respondent/data collection activity	Number of respondents	Responses per respondent	Hours per response	Total annual burden hours
Title III Supplemental Form to the Financial Status Report	56	2/yr	2	224
Total	56	2/yr	2	224

Dated: September 19, 2017.

Mary Lazare,

Principal Deputy Administrator.

[FR Doc. 2017-20666 Filed 9-26-17; 8:45 am]

BILLING CODE 4154-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2017-N-0001]

Advisory Committee; National Mammography Quality Assurance Advisory Committee; Renewal

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; renewal of advisory committee.

SUMMARY: The Food and Drug Administration (FDA) is announcing the renewal of the National Mammography Quality Assurance Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the National Mammography Quality Assurance Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until July 7, 2019.

DATES: Authority for the National Mammography Quality Assurance Advisory Committee will expire on July 7, 2017, unless the Commissioner formally determines that renewal is in the public interest.

FOR FURTHER INFORMATION CONTACT: Sara Anderson, Office of Device Evaluation, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. G616, Silver Spring, MD 20993-0002, 301-796-7047, Sara.Anderson@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: Pursuant to 41 CFR 102-3.65 and approval by the Department of Health and Human

Services (HHS) pursuant to 45 CFR part 11 and by the General Services Administration, FDA is announcing the renewal of the National Mammography Quality Assurance Advisory Committee (Committee). The Committee is a non-discretionary Federal advisory committee established to provide advice to the Commissioner. The HHS Secretary and, by delegation, the Assistant Secretary for the Office of Public Health and Science and the Commissioner are charged with the administration of the Federal Food, Drug, and Cosmetic Act and various provisions of the Public Health Service Act. The Mammography Quality Standards Act of 1992 amends the Public Health Service Act to establish national uniform quality and safety standards for mammography facilities. The Committee advises the HHS Secretary and, by delegation, the Commissioner in discharging their responsibilities with respect to establishing a mammography facilities certification program. The Committee shall advise FDA on:

- Developing appropriate quality standards and regulations for mammography facilities;
- Developing appropriate standards and regulations for bodies accrediting mammography facilities under this program;
- Developing regulations with respect to sanctions;
- Developing procedures for monitoring compliance with standards;
- Establishing a mechanism to investigate consumer complaints;
- Reporting new developments concerning breast imaging which should be considered in the oversight of mammography facilities;
- Determining whether there exists a shortage of mammography facilities in rural and health professional shortage areas and determining the effects of personnel on access to the services of such facilities in such areas;

- Determining whether there will exist a sufficient number of medical physicists after October 1, 1999; and

- Determining the costs and benefits of compliance with these requirements.

The Committee shall consist of a core of 15 members, including the Chair. Members and the Chair are selected by the Commissioner or designee from among physicians, practitioners, and other health professionals, whose clinical practice, research specialization, or professional expertise includes a significant focus on mammography. Members will be invited to serve for overlapping terms of up to 4 years. Almost all non-Federal members of this Committee serve as Special Government Employees. The core of voting members shall include at least four individuals from among national breast cancer or consumer health organizations with expertise in mammography, and at least two practicing physicians who provide mammography services. In addition to the voting members, the Committee shall include two nonvoting industry representatives who have expertise in mammography equipment. The Committee may include one technically qualified member, selected by the Commissioner or designee, who is identified with consumer interests.

Further information regarding the most recent charter and other information can be found at <https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Radiation-EmittingProducts/NationalMammographyQualityAssuranceAdvisoryCommittee/ucm520365.htm> or by contacting the Designated Federal Officer (see **FOR FURTHER INFORMATION CONTACT**). In light of the fact that no change has been made to the Committee name or description of duties, no amendment will be made to 21 CFR 14.100.

This document is issued under the Federal Advisory Committee Act (5 U.S.C. app.). For general information related to FDA advisory committees,

please visit us at <https://www.fda.gov/AdvisoryCommittees/default.htm>.

Dated: September 22, 2017.

Anna K. Abram,

Deputy Commissioner for Policy, Planning, Legislation, and Analysis.

[FR Doc. 2017-20683 Filed 9-26-17; 8:45 am]

BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Ryan White HIV/AIDS Program, Part F AIDS Education and Training Centers

AGENCY: Health Resources and Services Administration, HHS.

ACTION: Notice of non-competitive, HRSA-initiated, Secretary's Minority AIDS Initiative Fund (SMAIF) supplemental funding award: Fiscal Year (FY) 2017 Ryan White HIV/AIDS Program (RWHAP) AIDS Education and Training Centers (AETC) to the National Clinician Consultation Center (NCCC) at the University of California, San Francisco.

SUMMARY: This non-competitive supplemental funding award will provide a phone consultation line staffed by clinicians dedicated to providing technical support and real-time clinical consultation to health professionals who treat people living with HIV (PLWH) who are coinfecting with the hepatitis C virus (HCV).

FOR FURTHER INFORMATION CONTACT: Ms. Sherrilyn Crooks, Chief, HIV Education Branch, HIV/AIDS Bureau, Health Resources and Services Administration, 5600 Fishers Lane, 09N09, Rockville, MD 20857, Phone: (301) 443-7662, Email: scrooks@hrsa.gov.

SUPPLEMENTARY INFORMATION:

Intended Recipient of the Award: The University of California, San Francisco.
Amount of Non-Competitive Award: \$200,000.

Period of Funding: July 1, 2017, through June 30, 2018.

CFDA Number: 93.145.

Authority: The Consolidated Appropriations Act, 2017 (Pub. L. 115-31), Division H, Title II.

Justification

HRSA's SMAIF HIV/HCV initiatives seek to improve the prevention, screening, care, treatment, and cure of HCV in areas affected by HIV/HCV coinfection, particularly in disproportionately affected low-income, uninsured and underserved racial and ethnic minority populations in the

United States. Despite the fact that HIV treatment outcomes continue to improve among PLWH, HIV/HCV coinfection remains a major concern with approximately one quarter of PLWH also coinfecting with HCV.

The University of California, San Francisco's NCCC is funded under the RWHAP AETC Program, which comprises a network of three national centers and eight regional centers (with more than 130 local affiliated sites) that conduct targeted, multidisciplinary education, training, and technical assistance to health care providers who treat PLWH. The NCCC provides nationwide expert technical support, and clinical consultation services to health professionals who treat PLWH. Supplemental funding will enable the NCCC to leverage its existing infrastructure to add an HIV/HCV phone consultation line to deliver immediate clinical consultation and education services to RWHAP clinical providers funded through the SMAIF HIV/HCV initiatives and to clinical providers nationwide. Clinical providers will receive guidance based on up-to-date clinical HCV guidelines. Subject to the availability of funds and the recipient's satisfactory performance, up to \$200,000 will also be awarded in FY18 (budget period July 1, 2018 through June 30, 2019) and FY19 (budget period July 1, 2019 through June 30, 2020).

Denial of this request will prevent RWHAP clinical providers from achieving the goals of the SMAIF HIV/HCV initiative and from gaining critical and immediate access to a national network of HIV/HCV resources, including clinical experts who would provide education and technical assistance that meets the unique needs of this initiative.

Dated: September 14, 2017.

George Sigounas,
Administrator.

[FR Doc. 2017-20687 Filed 9-26-17; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Request for Comments on the Draft Department Strategic Plan for FY 2018-2022

AGENCY: Office of the Secretary, Office of the Assistant Secretary for Planning and Evaluation, Health and Human Services.

ACTION: Request for Comments on the Draft Strategic Plan FY 2018-2022.

SUMMARY: The Department of Health and Human Services (HHS) is seeking public comment on its draft Strategic Plan for Fiscal Years 2018-2022.

DATES: Submit comments on or before October 26, 2017.

ADDRESSES: Written comments can be provided by email, fax or U.S. mail.

Email: HHSPlan@hhs.gov.

Fax: (202) 690-5882.

Mail: U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, Strategic Planning Team, Attn: Strategic Plan Comments, 200 Independence Avenue SW., Room 415F, Washington, DC 20201.

FOR FURTHER INFORMATION CONTACT: Sarah Potter, (202) 260-6518.

SUPPLEMENTARY INFORMATION: The draft Department of Health and Human Services Strategic Plan FY 2018-2022 is provided as part of the strategic planning process under the Government Performance and Results Modernization Act of 2010 (GPRA-MA) (Pub. L. 111-352) to ensure that Agency stakeholders are given an opportunity to comment on this plan.

This document articulates how the Department will achieve its mission through five strategic goals. These five strategic goals are (1) Reform, Strengthen, and Modernize the Nation's Health Care System, (2) Protect the Health of Americans Where They Live, Learn, Work, and Play, (3) Strengthen the Economic and Social Well-Being of Americans across the Lifespan, (4) Foster Sound, Sustained Advances in Sciences, and (5) Promote Effective and Efficient Management and Stewardship. Each goal is supported by objectives and strategies.

The strategic planning consultation process is an opportunity for the Department to refine and strengthen the HHS Strategic Plan FY 2018-2022. The Department has made significant progress in its strategic and performance planning efforts. As we build on this progress we look forward to receiving your comments by October 26, 2017. The text of the draft HHS Strategic Plan FY 2018-2022 is available through the Department of Health and Human Services Web site at <https://www.hhs.gov/draft-strategic-plan>.

For comparison purposes, the current HHS Strategic Plan FY 2014-2018 can be viewed at <https://www.hhs.gov/about/strategic-plan/index.html>.

For those who may not have Internet access, a hard copy can be requested from the contact point, Sarah Potter, (202) 260-6518.